Eli Lilly plans to introduce a personalized diabetes management platform that integrates with technologies, including Dexcom’s continuous glucose monitoring (CGM) systems.
The platform, branded Tempo, features a reusable medical device that attaches to Lilly’s prefilled, disposable insulin pens and sends dose-related data to the compatible app. According to Medtechdive, the platform has three components: Tempo Smart Button, a device that records information about the delivery of insulin and shares it via Bluetooth; TempoSmart, an app that records insulin dose information and enables patients to share it with healthcare providers; and Tempo Pen, an insulin delivery device.
Patients attach the button to Tempo Pen to send insulin-dose information to TempoSmart. Capturing the data facilitates medication reminders, personalised education resources and feedback on blood glucose levels.
Lilly is enabling patients to bring more data into the system by integrating with other devices, notably Dexcom CGM systems and the Tempo blood glucose monitor. Tempo can also sync data with wearable devices from Fitbit, Garmin, Google Fit and the Apple Health app.
To read more, CLICK HERE.
